After it is primed, the CAR-T cells are locally induced to express a second chimeric receptor targeting two more homogeneous tumor-specific antigens [EPH receptor A2 (EphA2) antigen or IL13Rα2 antigen] so as to switch on their highly specific killing program [126]. Here, EPHA2 is linked to neoplasm.